Se habla español
Eye injections — more formally called intravitreal injections — are a cornerstone of modern retinal care for several sight-threatening conditions. Delivered directly into the vitreous cavity, these medications reach the back of the eye in concentrations far higher than topical or oral treatments can achieve. At Next Level Retina in Oak Brook, Illinois, Dr. Neel Lamba, MD, MBA, evaluates each patient individually to determine whether an intravitreal approach is the most appropriate way to preserve or improve central vision.
Intravitreal injections place medication into the gel-like vitreous that fills the eye, allowing active agents to act precisely at the site of retinal disease. This targeted delivery minimizes systemic exposure while maximizing the dose where it matters most — at the retina and macula. Common classes of medications administered this way include anti-VEGF agents, which limit abnormal blood vessel growth and leakage, and corticosteroids, which reduce inflammation and swelling when indicated.
The procedure itself is routinely performed in the office under strict sterile conditions. Before the injection, the eye is numbed with topical anesthetic and cleaned with an antiseptic solution. A brief, focused technique is used to place the medication through the white of the eye; most patients describe little more than pressure or momentary discomfort. The entire visit is typically efficient, allowing clinicians to combine treatment with imaging when needed to guide care.
Beyond the injection event, the therapeutic effect depends on the medication chosen and the biology of the disease. Some drugs act quickly to reduce fluid and improve vision, while others provide a more prolonged control of disease activity. Your provider will explain how each medication works and why a particular agent is recommended for your condition.
Intravitreal injections are used across a spectrum of retinal disorders where fluid, bleeding, or abnormal blood vessel activity threatens central vision. Selecting the right medication depends on the underlying cause — for example, whether the primary problem is abnormal vascular growth, leakage from damaged vessels, or inflammation. Individualized care means matching the mechanism of the disease with the mechanism of the drug.
Treatment decisions also take into account the severity and chronicity of the condition, your overall health, and prior responses to therapy. In many cases, injections halt progression of vision loss and in some patients can restore part of the vision that was lost. The goal is to stabilize the retina and preserve the best possible level of function for day-to-day activities like reading and driving.
Close monitoring is an essential part of this approach. Imaging technologies such as optical coherence tomography (OCT) let clinicians visualize retinal swelling and fluid with high precision, guiding both initial treatment and long-term adjustments to the regimen. This combination of targeted therapy and real-time imaging has transformed outcomes for several formerly devastating retinal diseases.
In the wet form of AMD, fragile new blood vessels grow beneath the macula and leak fluid or blood, causing distortion and central vision loss. Anti-VEGF injections are the primary treatment, aiming to halt vessel growth, reduce leakage, and often improve visual acuity. Regular injections and careful monitoring are typically needed to maintain the benefit over time.
Diabetic eye disease can weaken retinal vessels, allowing fluid to collect in the macula and impair sharp vision. Anti-VEGF medications are frequently used to reduce this swelling and stabilize vision; steroid injections may be considered when inflammation plays a larger role or when responses to anti-VEGF are incomplete.
When a retinal vein becomes blocked, fluid can build up in the macula and gas exchange may be impaired, producing vision loss. Intravitreal injections help reduce macular edema and limit secondary complications; early intervention often improves the chance of meaningful recovery of central vision.
Macular swelling may arise from a number of causes beyond diabetes and vein occlusion, including inflammatory conditions and surgical complications. Depending on the origin of the edema, either anti-VEGF agents or corticosteroid injections — or a combination over time — may provide the best control of fluid and symptoms.
Treatment with eye injections is rarely one-size-fits-all. Many patients begin with an initial series of treatments to gain rapid control of disease activity, after which the schedule is adjusted based on response. Two commonly used approaches are fixed-interval dosing and individualized strategies such as “treat-and-extend,” which lengthen the interval between injections when the retina remains stable.
Decisions about timing are driven by both objective test results and how you are doing functionally. OCT scans reveal whether fluid remains in the retina; visual acuity testing and your symptom report help complete the clinical picture. The objective is to use the fewest injections necessary to keep the disease controlled while maintaining your quality of life.
Ongoing evaluation at each visit allows your clinician to escalate, maintain, or relax the treatment plan as warranted. Some patients achieve long stretches without injections, whereas others need regular dosing to prevent recurrence. Your treatment plan will be documented and discussed in plain language so you know what to expect at every stage.
Intravitreal injections are among the most commonly performed procedures in ophthalmology and have a strong safety record when performed under sterile conditions. Common, mild side effects include temporary redness, minor irritation, or a sensation of pressure in the eye immediately after the injection. These symptoms usually resolve within a day or two and are expected parts of the recovery process.
More serious complications are rare but important to recognize, and your care team will review warning signs before you leave the clinic. If you experience increasing pain, sudden vision loss, a significant increase in redness, or light sensitivity after an injection, you should notify your provider promptly so that any necessary evaluation or treatment can be arranged.
Practical aftercare is straightforward: avoid rubbing the treated eye, follow any short-term medication instructions given by your clinician, and attend scheduled follow-up visits. Because the underlying diseases treated with intravitreal injections can be chronic, consistent follow-up and adherence to the agreed plan are essential to achieving the best possible long-term outcomes.
For many patients, intravitreal injections convert a rapidly progressive threat to vision into a manageable, chronic condition. Some people experience meaningful visual improvement; others achieve stabilization that preserves their ability to perform daily tasks. Long-term success depends on early intervention, appropriate choice of medication, and repeat treatments when necessary.
Shared decision-making is central to this process. Your clinician will explain the rationale for the recommended medication, possible alternatives, and how the treatment fits into your overall health and lifestyle. Questions about how the injections may affect your daily routine, travel, or work are welcomed and help shape a plan that is both effective and realistic.
If you have concerns about injections or want to better understand the role they may play in preserving your vision, the team at Next Level Retina can help you weigh the options and develop a tailored plan. Contact us for more information or to discuss whether intravitreal therapy might be right for your retinal condition.
Intravitreal injections, commonly called eye injections, deliver medication directly into the vitreous cavity at the back of the eye. This targeted approach lets therapeutic agents reach the retina and macula in concentrations that topical or oral treatments cannot achieve. The procedure is used to treat a range of sight-threatening retinal conditions and is performed in a controlled office setting by a retina specialist.
Medications given by injection include classes that block abnormal blood vessel growth, reduce leakage, or lessen inflammation. Treatment goals vary by disease and patient but generally focus on preserving or improving central vision and stabilizing retinal anatomy. Your clinician will explain the specific medication chosen and the expected benefits for your condition.
Eye injections place medication into the gel-like vitreous so active agents act close to the retina where disease occurs. By delivering drugs directly to the site of pathology, the treatment maximizes local effect while minimizing systemic exposure. This direct route is especially important for conditions involving macular swelling, abnormal vessels, or retinal inflammation.
Common medication types include anti-VEGF agents that limit abnormal vessel growth and leakage, and corticosteroids that reduce inflammation and fluid accumulation. The choice of agent depends on the underlying mechanism of disease and prior treatment response. Your retina specialist will review how the selected medication works and why it is recommended for your eye.
Intravitreal injections are used for several retinal diseases where fluid, bleeding, or abnormal vessel growth threatens central vision. Typical indications include wet age-related macular degeneration, diabetic macular edema and proliferative diabetic retinopathy, retinal vein occlusion with macular edema, and certain forms of inflammatory or postoperative macular swelling. Each condition involves different disease processes that guide medication selection.
Treatment is individualized based on disease severity, chronicity, overall health, and prior responses to therapy. Imaging such as optical coherence tomography (OCT) helps identify and quantify retinal fluid, which informs both initial therapy and subsequent adjustments. With targeted treatment and close monitoring, many patients experience stabilization and in some cases improvement in vision.
The procedure begins with topical anesthetic to numb the eye and an antiseptic cleaning of the eyelids and surface. Under sterile conditions, the clinician uses a brief, focused technique to introduce the medication through the white of the eye; most patients report little more than pressure or a momentary sensation. The actual injection typically takes only seconds, and the overall visit is often efficient.
After the injection there may be a short observation period and, when appropriate, imaging such as OCT to document the retina. Some visits combine treatment with diagnostic testing to guide ongoing care, which can add modest time to the appointment. If you have specific concerns about logistics or timing, mention them when scheduling so the team can plan accordingly.
Mild, common effects include temporary redness, minor irritation, tearing, or a sensation of pressure in the injected eye that typically resolves within a day or two. These expected responses are part of normal recovery and usually do not require additional treatment. Your clinician will provide specific aftercare steps to reduce irritation and support healing.
Serious complications are uncommon but important to recognize, and prompt evaluation is essential if they occur. Seek urgent care if you experience increasing or severe pain, sudden vision loss, a marked increase in redness, or new light sensitivity after an injection. The retina team will give clear instructions on warning signs and how to contact the practice if problems arise.
Injection schedules are individualized and typically begin with an initial series to gain control of disease activity, followed by adjustments based on the response. Two common approaches are fixed-interval dosing and individualized strategies such as treat-and-extend, which lengthen the interval between injections when the retina remains stable. Decisions about timing are driven by OCT findings, visual acuity, and your reported symptoms.
Because retinal disease biology varies and can change, the treatment plan frequently evolves over months to years. Some patients reach long stretches without injections, while others require ongoing regular dosing to maintain control. The goal is always to use the fewest injections necessary to preserve vision and quality of life, and your clinician will discuss rationale and expected milestones at each stage.
The effect of injections depends on the underlying disease, how advanced it is at the time of treatment, and how the retina responds biologically. In many cases injections can reduce fluid and improve retinal anatomy, which leads to measurable visual gains. In other cases the primary benefit is stabilization—halting progression and preserving existing central vision.
Early intervention and consistent follow-up improve the chance of meaningful recovery, but outcomes vary among individuals. Your retina specialist will set realistic expectations based on your diagnosis, prior treatment history, and objective imaging. Shared decision-making helps align therapy with your visual goals and daily needs.
Intravitreal injections are commonly used in patients with diabetes and many other systemic conditions and are generally safe when recommended by a retina specialist. Before treatment your clinician will review your medical history, current medications, and any systemic factors that could affect care. Coordination with your primary care physician or other specialists may be advised for complex medical situations.
Certain medications or health issues might prompt special precautions, but the benefits of treating sight-threatening retinal disease often outweigh potential risks. The retina team will tailor the plan to your overall health, monitor you closely, and provide guidance on when additional medical input is needed. If you have concerns about specific conditions or medications, raise them during your consultation so they can be addressed.
Your retina will be followed with a combination of clinic exams, visual acuity testing, and imaging such as OCT to detect retinal swelling and fluid with high precision. These objective measures help determine whether the disease is controlled or if treatment needs to be escalated. Regular monitoring allows clinicians to adjust intervals, change medications, or add therapies as indicated by the clinical picture.
In addition to scheduled visits, you should report any sudden changes in vision or new symptoms promptly, as these may signal recurrence or complications. The monitoring schedule is personalized and may be intensified early in treatment or when disease activity is variable. Clear communication with the clinic helps ensure timely care and the best possible outcomes.
Preparing for injections includes bringing an up-to-date list of medications and medical conditions, arranging transportation if you prefer not to drive afterwards, and preparing questions about goals and what to expect. It helps to review any prior imaging or treatment records and share them with the team so care can be coordinated efficiently. Being informed and organized at the first visit sets the stage for effective, personalized management.
Active partnership with your retina team improves long-term outcomes by ensuring adherence to follow-up, reporting symptom changes, and discussing lifestyle or medical factors that may affect treatment. The office of Next Level Retina will outline a clear plan, provide contact instructions for concerns, and involve you in decisions about scheduling and medication choices. Open communication and timely follow-up are key components of successful, sustained care.
Phone:
Fax:
